Economic modelling of antiplatelet therapy in the secondary prevention of stroke

Journal of Medical Economics

Volumn 7, Issue 117-134, 2004, Pages 117-134

  Beard, Stephen M ^a   Gaffney, Louise ^a   Bamber, Luke ^b   De Platchett, Jason ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

Antiplatelet; Cost effectiveness; Dipyridamole; Economic; Model; Stroke; UK

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC ASPECT; HUMAN; QUALITY ADJUSTED LIFE YEAR; RESOURCE MANAGEMENT; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 11144267129     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200407117134     Document Type: Review

References (23)

1. National Service Framework for Older People. March 2001. London: Department of Health.
2. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Science 1996; 143: 1-13.
3. European Stroke Prevention Study 2. Efficacy and safety data. Journal of Neurological Science. 1997; 151 (Suppl): S1-77.
4. Department of Health. Saving Lives: Our Healthier Nation. July 1999. London: HMSO.
5. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics 1999; 16: 577-593.
6. The Stroke Association. Stroke Fact Sheet. http://www.stroke.org.uk/ noticeboard/[facts.htm] accessed December 2003.
7. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003; 21 (Suppl 1): 43-50.
8. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 2002; 324: 71-86.
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
10. Van Swieten JC, Koudstall PJ, Visser MC et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
11. Rankin J. Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scottish Medical Journal 1957; 2: 200-215.
12. Bamford J, Sandercock P, Dennis M et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-86. 1. Methodology, demography and incident cases of first ever stroke. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1373-1380.
13. Burn J, Dennis M, Bamford J et al. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994; 25: 333-337.
14. NHS Reference Costs 2001. Department of Health: Leeds, 2001.
15. Personal Social Services Research Unit (PSSRU). 2002. Unit Costs of Health and Social Care. Canterbury: PSSRU.
16. British National Formulary: version 44; 2002.
17. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke 2001; 32: 964-972.
18. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. Journal of the American Medical Association 1995; 274: 1839-1845.
19. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001; 32: 1425-1429.
20. NICE. Guidance for Manufacturers and Sponsors. Technology Appraisals Process Series No 5. June 2001. London: National Institute for Clinical Excellence.
21. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value in Health 2002; 5: 82-97.
22. Hedman J, Kaprio J, Poss T, Nieminen M M. Prevalance of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. International Journal of Epidemiology 1999; 28: 717-722.
23. Beech R, Rudd AG, Tilling K, Wolfe CD. Economic consequences of early inpatient discharge to community-based rehabilitation for stroke in an inner-London teaching hospital. Stroke 1999; 30: 729-735.